ViewMind announces the appointment of Matthew Heller as Vice President Business Development
ViewMind, the global leader in the precision measurement of neurocognitive health based on ocular digital phenotyping, today announces that Matthew Heller has been appointed VP Business Development.
Matthew is dedicated to the transformation of neuro and mental health care through the formation of strategic partnerships, alliances, and commercial relationships. Matthew has worked for several companies in the biotechnology, artificial intelligence, digital therapeutics, pharmacy, and diagnostics areas and always with a neuro, psychiatry, and mental health focus.
“I am very excited about the opportunity at ViewMind to build transformative partnerships to support precision drug development and precision patient care”, said Matthew Heller, “ViewMind’s technology is a game changer in its ability to accurately, non-invasively, assess brain health and treatment impact”.
“Matthew is thoughtful, passionate about neurology and highly motivated to apply his blend of skills and experience towards the commercialization of ViewMind’s technology through strategic partnerships to bring about what will be inevitable and momentous change in brain health diagnosis, drug development and treatment management”, commented Mark Edwards, ViewMind’s Co-founder, CEO, and Chairman. “We are thrilled to be adding an executive of Matthew’s caliber to the management team and look forward to working together to impact millions of people’s lives with cognitive issues.”
Heller has a Bachelors in neuroscience from Boston University and a Masters from Brown University in business engineering and biotechnology.